Sai Life Sciences shares hit a fresh 52-week high on Monday after strong Q2 results and bullish brokerage commentary. Jefferies retained its Buy rating and raised its target price to Rs 2,050, citing healthy CRO and CDMO growth, a strengthening pipeline and improved earnings prospects.